BDX
BECTON DICKINSON & COEvidence as of 2026-09-02Overview · BECTON DICKINSON & CO
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis…
Management team
- Mr. Greg Rodetis · Senior VP, Treasurer & Head of Investor RelationsFind on LinkedIn
- Ms. Denise Russell Fleming · Executive VP of Technology & Global Services and Chief Information OfficerFind on LinkedIn
- Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. · Senior VP & Chief Scientific OfficerFind on LinkedIn
- Ms. Elizabeth McCombs · Executive VP & Chief Technology OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.0 on a −2 to +2 scale — was −0.0 before the debate changed the read.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed (+0.0 of a possible +2; was -0.0 before debate) · confidence high. Reported revenues were USD 5,252,000,000 in Q1 2026 (fiscal quarter ended 2025-12-31), fell to USD 4,714,000,000 in Q2 2026 (fiscal quarter ended 2026-03-31) and rose to USD 4,983,000,000 in Q3 2026 (fiscal quarter ended 2026-06-30). Operating income compressed sharply to USD 93,000,000 in Q2 2026 from USD 552,000,000 in Q1 2026 and rebounded to USD 663,000,000 in Q3 2026, implying operating margins of ~ 10.5% in Q1 2026, ~ 2.0% in Q2 2026 and ~ 13.3% in Q3 2026; net income swung from USD 382,000,000 (Q1 2026) to a loss of USD 311,000,000 (Q2 2026) and back to USD 377,000,000 (Q3 2026).
Balance-sheet and capital structure lines show weighted-average diluted shares falling from 285,845,000 in Q1 2026 to 275,158,000 in Q3 2026 and point-in-time long-term noncurrent debt declining from USD 17,940,000,000 as of 2024-09-30 to USD 13,511,000,000 as of 2026-06-30; cash and cash equivalents moved modestly around USD 700–813,000,000 on the reported dates. Market signals are mixed-to-constructive: momentum_3m +30.5%, golden_cross true with price_vs_sma50 +11.6% and price_vs_sma200 +18.4% (as of 2026-09-01), low market sensitivity (beta_spy 0.35), but elevated volatility (vol_90d_annualized +30.4%) and a three‑year max drawdown of -39.6%. Valuation snapshots show trailing twelve‑month FCF of USD 3.02 billion (FCF/share USD 10.9755), implied FCF growth embedded at 5.18%, price-to-FCF 17.05, EV/EBITDA 14.62, trailing P/E 51.98, enterprise value USD 63,772,018,016 and market cap USD 50,969,018,016 (price USD 187.12 on 2026-09-01). Insider filings report aggregate sales of about USD 799k in the 180‑day window and no open‑market insider purchases in the supplied data.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenues were USD 5,252,000,000 for fiscal Q1 2026 (2025-10-01 to 2025-12-31, 3mo) and fell to USD 4,714,000,000 in fiscal Q2 2026 (2026-01-01 to 2026-03-31, 3mo) before rising to USD 4,983,000,000 in fiscal Q3 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0000010795-26-000005Operating income showed a sharp compression in fiscal Q2 2026 to USD 93,000,000 (from USD 552,000,000 in fiscal Q1 2026) and rebounded to USD 663,000,000 in fiscal Q3 2026; that implies operating margins of ~10.5% in fiscal Q1 2026 (552 / 5,252), ~2.0% in fiscal Q2 2026 (93 / 4,714), and ~13.3% in fiscal Q3 2026 (663 / 4,983).
XBRL companyfacts · 0000010795-26-000026Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 insider filing was submitted with the 4 filed 14 August 2026, filed 2026-08-14.
4 filed 2026-08-14A Form 4 insider filing was submitted with the 4 filed 24 August 2026, filed 2026-08-24.
4 filed 2026-08-24Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum measures are positive: momentum_3m is +30.5%, momentum_6m is +8.8%, and momentum_12_1 is +24.4%, with rank_momentum_6m at the 55th percentile and rank_momentum_12_1 at the 66th percentile of a 547-stock universe (as of 2026-09-01).
Moneyta signal set · 2026-09-01weakened in debateTechnical trend indicators are constructive on the supplied dates: golden_cross is true, price_vs_sma50 is +11.6%, and price_vs_sma200 is +18.4% (as of 2026-09-01, cross_age_days = 17).
Moneyta signal set · 2026-09-01Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02, BDX is held in multiple large ETFs including XLV (weight 1.01%), VYM (0.32%), VTV (0.30%), VOO (0.13%), SCHX (0.12%), SCHB (0.09%), and IVV (0.06%).
ETF constituents · market dataThe latest reported 13F quarter (as of 2026-03-31) shows total institutional 13F value of $3.2M, with a single reported holder (Dakota Wealth Management) and quarter-over-quarter value change of -30.1%.
13F holdings · 1 filers · as of 2026-03-31weakened in debateReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A report on 1 September 2026 indicates UBS AM trimmed its Becton, Dickinson and Company stake by 110,762 shares (a 5.9% reduction) in the second quarter.
News · thelincolnianonline.com · 2026-09-01A report on 31 August 2026 states Flputnam Investment Management Co. boosted its Becton, Dickinson and Company holdings by 293.8% in the second quarter, owning 10,080 shares after additional purchases.
News · thelincolnianonline.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Insiders reported aggregate sales of "$799k" in the 180-day window covered by the parsed transactions.
Form 4 · Polen Thomas E Jr (Chairman, CEO and President) · $7.2M code M · 2026-08-13No insider open-market purchases are recorded in the provided data; the parsed summary shows "bought": "$0" and "distinct_buyers": 0.
Form 4 · Feld Michael (EVP, Chief Revenue Officer) · $0 code F · 2026-08-20Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 5.18% (0.0518) that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month free cash flow (FCF) is $3.02 billion and FCF per share is $10.9755, based on shares outstanding of 272,386,800 as of 2026-06-30.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several pieces of the supplied evidence jointly support a constructive read: long-term debt has declined materially between 2024-09-30 and 2026-06-30, weighted-average diluted shares outstanding and point-in-time shares have fallen (supporting per-share metrics), and operating income and net income both showed a sharp rebound in fiscal Q3 2026 after a compression in Q2. Market signals align with those fundamentals on the supplied dates: positive momentum, a recent golden cross with price above the 50- and 200-day SMAs, low sensitivity to the S&P 500, and an income profile with a 2.24% trailing dividend yield and multi-year dividend growth. Valuation and cash-flow evidence (TTM FCF $3.02B, FCF/share $10.98, implied market FCF growth ~5.18%, and moderate price/FCF and EV/EBITDA multiples) provide context that the market price embeds a reasonable free-cash-flow growth expectation. Taken together, these claims form a coherent snapshot of improving operating performance, balance-sheet de-leveraging, shareholder-friendly share count trends, and constructive technical/momentum positioning on the supplied dates.
Chair's verdict, claim by claim
Fragility · computed, not argued
diversified0.27
35 surviving claims rest on 20 distinct sources; the heaviest analyst carries 17% of them, and 97% of what the desk raised survived the debate.
The read is moderately robust in source breadth but shows analyst concentration and strong survivorship through debate. Because one analyst accounts for a meaningful share and most claims survived review, treat individual items as well-vetted but still somewhat dependent on a few contributors and the same underlying documents.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
90-day volatility ranks 2nd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
dividend yield ranks 1st of 3 in Medical Instruments & Supplies (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
16 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.3 to the score
3 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.2 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
3 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−0.8 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on BDX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.